Corundum Neuroscience’s Post

That's a wrap for the RESI JPM 2025 Conference. M4D was proud to support its clients while engaging with neurovascular and cardiovascular entrepreneurs bringing their technology to market. Most discussions focused on the new era in Medtech, and the healthy amount of funding and M&A activity bringing new optimism and energy for 2025. Looking forward to an exciting and busy year supporting these visionaries impacting patient lives worldwide. See you next year! #m4d #arttopart #neuro #neurovascular #endovascular #interventionalradiology #contractmanufacturing #asiamedtech #asiainnovation #prototyping #rapidprototyping #medicaldevicemanufacturing #researchanddevelopment #medtech #medicaldevice #startups #innovation #regulatory #quality

M4D has a spectrum of catheter capabilities, including over the shaft winding utilizing a bunk bed winder we can coil wind over your liner or shaft material. With closed pitch and large pitch winding, we are able to wind over your liner with ease and in a consistent fashion. To learn more about all our catheter capabilities, visit: https://lnkd.in/gPhGMGPb #m4d #arttopart #neuro #neurovascular #endovascular #interventionalradiology #contractmanufacturing #asiamedtech #asiainnovation #prototyping #rapidprototyping #medicaldevicemanufacturing #researchanddevelopment #medtech #medicaldevice #startups #innovation #regulatory #quality

From Art to Part, M4D's extensive design and development capabilities have you covered in all aspects of the product development lifecycle. Here our team utilizes radial force testing machine has purpose-built software to measure and record radial stiffness and strength, chronic outward force during expansion, and radial reactive force during compression of interventional devices. To learn about the other spectrum of M4D's product development services visit: https://lnkd.in/gPsR8_vG #m4d #arttopart #neuro #neurovascular #endovascular #interventionalradiology #contractmanufacturing #asiamedtech #asiainnovation #prototyping #rapidprototyping #medicaldevicemanufacturing #researchanddevelopment #medtech #medicaldevice #startups #innovation #regulatory #quality

The rise in neurological disorders like Alzheimer’s, epilepsy, and Parkinson’s is driving demand for innovative solutions. High-tech start-ups are leading this transformation, developing cutting-edge therapies, diagnostics, and medical devices. At Norn Ventures, we’re proud to support this critical work with our £100 million healthcare and med-tech fund, launching in Q2 2025. We focus on start-ups innovating in: ✔️ Targeted Therapies: Breakthrough drugs for chronic neurological conditions. ✔️ Medical Devices: Tools like wearable EEGs and neurostimulation devices. ✔️Digital Health: AI-powered platforms for early diagnosis and personalised care. Neurology is primed for growth, with advancements in genomics, robotics, and neuroimaging unlocking new possibilities. Backed by governments and private equity, this sector is redefining healthcare. Join us in supporting the future of neurology and improving millions of lives. Contact us or Barry Ritchie to learn more. #HealthcareInnovation #MedTech #ImpactInvesting #NornVentures

Private equity firms have been increasingly drawn to neurology, recognising its significant market potential and societal impact. Startups in this space are not only addressing urgent medical needs but also benefiting from advancements in complementary fields like genomics, robotics, and bioengineering. The commercialization of innovations, such as advanced brain imaging tools and minimally invasive neurosurgical devices, is creating exciting opportunities for investors. Moreover, governments and healthcare organizations worldwide are prioritising neurological research, providing grants, subsidies, and regulatory support that enhance the sector’s attractiveness to private investors. The Path Ahead Norn Ventures envisions its healthcare and medtech fund as a platform for scaling transformative solutions in neurology. By partnering with visionary founders and fostering long-term collaboration, we aim to deliver both financial returns and meaningful societal impact. As the world grapples with the growing challenge of neurological disorders, high-tech startups are uniquely positioned to lead the charge. With Norn Ventures’ strategic backing, these firms have the potential to redefine the future of neurology and improve millions of lives globally. https://lnkd.in/ebwV5DHx #Investors #privateequity #fund #healthcare #neurology

Exciting news from Robeauté! The #medtech startup has raised $28 million to advance its #neurosurgical microrobots. This funding will help start human trials in 2026 and expand US operations. Here's why this is groundbreaking: #Innovative #Technology: Robeauté's microrobots, the size of a grain of rice, can navigate the brain's complex pathways, offering precise targeting and multi-site access. Sustainability and Growth: With over 50 patents, Robeauté is set to transform neurosurgery and improve patient outcomes with personalized, precision medicine. Strategic Partnerships: Collaborations with Brainlab and other investors will support their mission to empower neurosurgeons with cutting-edge tools. Bertrand Duplat, co-founder and CEO of Robeauté, stated: "Microrobots hold untapped potential in medicine. Current neurosurgery is invasive and struggles with the blood-brain barrier. Our microrobots offer unparalleled brain access for personalized, precision medicine, transforming treatments and outcomes." Joana Cartocci, co-founder and COO of Robeauté: "Our microrobots will revolutionize neurosurgery, acting like a 'brain gardener' to tend to the organ from within. Starting with advanced biopsy, the potential is limitless. We're proud of our European roots and excited to expand to the US." Ian Hogarth, partner at Plural: "Robeauté's technology could transform neurosurgery and how drug companies find solutions. By gathering brain data, we can learn more about incurable diseases and enable personalized treatment." Filip Felician Dames, Founding Partner at Cherry Ventures: "Neurodegenerative diseases are a global challenge. Robeauté's work at the intersection of robotics, AI, and medicine is pioneering a revolutionary neurosurgical microbot, embodying frontier technology." How do you see microrobots changing the future of medicine? Share your thoughts! #MedTech #Innovation #Neurosurgery #Robotics #Healthcare #medical #technology

BrainSightAI, a Bengaluru-based neuroscience startup, has successfully raised $5 million in a Pre-Series A funding round. This round was led by IAN Alpha Fund, with contributions from IvyCap Ventures, Silver Needle, and existing investors. Founded in 2019 by Laina Emmanuel and Dr. Rimjhim Agrawal, BrainSightAI is making strides with its innovative platform, VoxelBox. The platform uses connectomics to map neural connections, aiding in the diagnosis and treatment of complex brain disorders and tumors. The funding will support BrainSightAI's growth, but it also aligns with a broader vision. The company plans to expand its presence in Tier 1 cities and enter Tier 2 markets, while also broadening its focus to include neurological and psychiatric care, aiming to better serve patients across India. CEO Laina Emmanuel highlights the immense potential of connectomics for advancing personalized brain care. The team is excited to work with investors who share their vision of creating world-class solutions from India. BrainSightAI is also pursuing FDA certification to enter the U.S. market. 💡 How do you see technology transforming healthcare in the coming years? Let's discuss! #Neuroscience #HealthcareInnovation #StartupFunding #BrainCare #IndiaStartups

The impact of Federal cuts to health and science research are being felt today by the research and government community, but they will be felt tomorrow by investor community seeking new companies in #medtech #neurotech #mentalhealth #pain #neurology #dementia and many other areas. Kip says it bluntly: "The North American Neuromodulation Society (NANS) meeting represents literally billions of dollars of economic activity each year for cutting edge therapies that treat hundreds of health conditions that drugs/biologics have not been able to dent. 𝐓𝐡𝐞𝐫𝐞'𝐬 𝐧𝐨𝐭 𝐚 𝐝𝐚𝐦𝐧 𝐨𝐧𝐞 𝐨𝐟 𝐭𝐡𝐞𝐦 𝐈 𝐜𝐚𝐧'𝐭 𝐩𝐨𝐢𝐧𝐭 𝐭𝐨 𝐚𝐧𝐝 𝐭𝐞𝐥𝐥 𝐲𝐨𝐮 𝐞𝐱𝐩𝐥𝐢𝐜𝐢𝐭𝐥𝐲 𝐡𝐨𝐰 𝐭𝐡𝐞𝐢𝐫 𝐜𝐨𝐦𝐩𝐚𝐧𝐲 𝐰𝐚𝐬 𝐞𝐢𝐭𝐡𝐞𝐫 𝐝𝐢𝐫𝐞𝐜𝐭𝐥𝐲 𝐬𝐮𝐩𝐩𝐨𝐫𝐭𝐞𝐝 𝐛𝐲 𝐠𝐨𝐯𝐞𝐫𝐧𝐦𝐞𝐧𝐭 𝐟𝐮𝐧𝐝𝐢𝐧𝐠 𝐢𝐧 𝐭𝐡𝐞 𝐞𝐚𝐫𝐥𝐲 𝐝𝐚𝐲𝐬 when it was just an idea, leveraged basic science funded a decade or more ago by government funded research, and/or was staffed by people who got their training and direct experience in neurotech to help people through government funded research labs. 𝐓𝐡𝐞 𝐞𝐧𝐭𝐢𝐫𝐞 𝐞𝐜𝐨𝐬𝐲𝐬𝐭𝐞𝐦 𝐨𝐟 𝐧𝐞𝐮𝐫𝐨𝐭𝐞𝐜𝐡 𝐢𝐬 𝐜𝐫𝐢𝐭𝐢𝐜𝐚𝐥𝐥𝐲 𝐝𝐞𝐩𝐞𝐧𝐝𝐞𝐧𝐭 𝐨𝐧 𝐧𝐨𝐧-𝐝𝐢𝐥𝐮𝐭𝐢𝐯𝐞 𝐠𝐨𝐯𝐞𝐫𝐧𝐦𝐞𝐧𝐭 𝐟𝐮𝐧𝐝𝐢𝐧𝐠 𝐭𝐨 𝐝𝐞𝐫𝐢𝐬𝐤 𝐢𝐝𝐞𝐚𝐬/𝐭𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐲 prior to angels/VC being willing to invest to take it the next step to create jobs and help patients." #leadership #science #research

M4D has a spectrum of catheter capabilities, including over the shaft winding utilizing a bunk bed winder we can coil wind over your liner or shaft material. With closed pitch and large pitch winding, we can wind over your liner easily and consistently. To learn more about all our catheter capabilities, visit: https://lnkd.in/gPhGMGPb #m4d #catheter #overtheshaftwinding #capabilities #neuro #neurovascular #prototyping #contractmanufacturing #rapidprototyping #medtech #medicaldevice #researchanddevelopment #entrepreneurs #startsups #innovation #designanddevelopment #manufacturing

A promising new approach that could slow, stop or prevent nerves from dying in diseases like ALS may get its first test in patients next year. Nura Bio raised $68M for clinical tests of its SARM1 inhibitor to stop nerve degeneration. I talked to Shilpa Sambashivan, who was recently promoted to CEO, to learn more about the approach. Read more in Endpoints News https://lnkd.in/eWTujwe2 #nervedegeneration #neurodegeneration #neurological #neuroscience #axondegeneration #SARM1 #SARM1inhibitor #ALS #multiplesclerosis #TBI #traumaticbraininjury #neuropathy #biotech #startup